Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.13
    -0.94 (-5.85%)

    Market Cap: $1.72B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sarepta Therapeutics Inc (SRPT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Sarepta Therapeutics are Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM) and Structure Therapeutics Inc. American Depositary Shares (GPCR). By market cap, Sarepta Therapeutics ranks 8th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.

    Peer Comparison

    SRPT's ROIC of -3.2% is above the peer median of -65.4%, and its revenue growth of -4.5% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Sarepta Therapeutics (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Recursion Pharmaceuticals Inc (RXRX)$1.99BN/A23.1x0.0%-51.8%258.5%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Stoke Therapeutics Inc (STOK)$1.75BN/A64.5x0.0%N/A5.9%0.00%
    Silence Therapeutics PLC (SLN)$1.23BN/A882.5x0.0%N/A197.2%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Palvella Therapeutics, Inc (PVLA)$2.23BN/AN/A0.0%N/A0.0%0.00%
    Rapport Therapeutics, Inc. Common Stock (RAPP)$1.55BN/A59.3x0.0%N/A0.0%0.00%
    Verastem Inc (VSTM)$1.03BN/A7.8x-178.4%-110.4%113.6%0.00%
    Replimune Group Inc (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Peer median$1.87BN/A23.1x0.0%-65.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Sarepta Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Recursion Pharmaceuticals Inc (RXRX)
    Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry...
    RXRX competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Septerna, Inc. Common Stock (SEPN)
    Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform.
    SEPN competitors
    Stoke Therapeutics Inc (STOK)
    Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious...
    STOK competitors
    Silence Therapeutics PLC (SLN)
    Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology...
    SLN competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Palvella Therapeutics, Inc (PVLA)
    Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from...
    PVLA competitors
    Rapport Therapeutics, Inc. Common Stock (RAPP)
    Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases...
    RAPP competitors
    Verastem Inc (VSTM)
    Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients.
    VSTM competitors
    Replimune Group Inc (REPL)
    Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
    REPL competitors

    Frequently Asked Questions About SRPT

    Who are Sarepta Therapeutics' main competitors?

    The companies most similar to Sarepta Therapeutics include Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Structure Therapeutics Inc. American Depositary Shares (GPCR), Septerna, Inc. Common Stock (SEPN) and Stoke Therapeutics (STOK), listed from the closest match.

    Who is Sarepta Therapeutics' biggest competitor?

    Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Recursion Pharmaceuticals (RXRX) is the closest match by business profile, size, sector and industry.

    How does SRPT stock compare with its competitors?

    SRPT's P/S is 0.8x against a peer median of 23.1x; its net margin is -5.9% against a peer median of 0.0%.

    Which of Sarepta Therapeutics' competitors pays a higher dividend?

    Sarepta Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Sarepta Therapeutics bigger than its competitors?

    No. Sarepta Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.